FMT in Gut aGVHD Treated
Department of Hematology of First Affiliated Hospital of Soochow University
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: xiaofei qi
- Phone Number: 1-86-512-67780410
- Email: qixiaofei@suda.edu.cn
Study Locations
-
-
Jiangsu
-
Suzhou, Jiangsu, China, 215006
- Recruiting
- 中国
-
Contact:
- xiaofei qi
- Phone Number: 051265223637
- Email: qixiaofei@suda.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- gut GVHD
Exclusion Criteria:
- Age>60; or Age<10
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
times of stool
Time Frame: 24hours,48hours,72hours, 96hours,fifth day,sixth day, a week
|
Change from stool times in a week
|
24hours,48hours,72hours, 96hours,fifth day,sixth day, a week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
volume in milliliter of stool
Time Frame: 24hours,48hours,72hours, 96hours,fifth day,sixth day, a week
|
Change from stool volume in a week
|
24hours,48hours,72hours, 96hours,fifth day,sixth day, a week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: depei wu, first affiliated of Soochow university
Publications and helpful links
General Publications
- Liu Y, Zhao Y, Qi J, Ma X, Qi X, Wu D, Xu Y. Fecal microbiota transplantation combined with ruxolitinib as a salvage treatment for intestinal steroid-refractory acute GVHD. Exp Hematol Oncol. 2022 Nov 9;11(1):96. doi: 10.1186/s40164-022-00350-6.
- Zhao Y, Li X, Zhou Y, Gao J, Jiao Y, Zhu B, Wu D, Qi X. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial. Front Immunol. 2021 Jun 17;12:678476. doi: 10.3389/fimmu.2021.678476. eCollection 2021.
- Qi X, Li X, Zhao Y, Wu X, Chen F, Ma X, Zhang F, Wu D. Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study. Front Immunol. 2018 Sep 25;9:2195. doi: 10.3389/fimmu.2018.02195. eCollection 2018.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- FMT2017002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute-graft-versus-host Disease
-
NCT02652130CompletedGrade B Acute Graft Versus Host Disease | Grade C Acute Graft Versus Host Disease | Grade D Acute Graft Versus Host Disease
-
NCT01903473TerminatedChronic Graft-Versus-Host Disease | Acute Graft-Versus-Host Disease | Steroid Refractory Graft-Versus-Host Disease
-
NCT03339297CompletedAcute-graft-versus-host Disease | Graft-versus-host Disease
-
NCT04280471WithdrawnAcute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host Disease
-
NCT03327857CompletedSteroid-refractory Acute Graft-versus-Host Disease | Treatment-refractory Acute Graft-versus-Host Disease
-
NCT07070674RecruitingAcute Graft-versus-Host Disease
-
NCT06949267Not yet recruitingAcute Graft-versus-Host Disease
-
NCT06490562Not yet recruitingAcute Graft-versus-host Disease
-
NCT05352269RecruitingAcute-graft-versus-host Disease
-
NCT03847844CompletedAcute-graft-versus-host Disease
Clinical Trials on Fecal microbiota
-
NCT03298048Terminated
-
NCT04577729TerminatedMalignant Melanoma Stage III | Malignant Melanoma Stage IV | Fecal Microbiota Transplantation
-
NCT07597421Not yet recruitingParkinson's Disease
-
NCT06376331RecruitingAttention-deficit/Hyperactivity Disorder
-
NCT07622849Enrolling by invitationTransplant-related Gastrointestinal Mucositis
-
NCT03819803RecruitingGraft Versus Host Disease in GI Tract
-
NCT06591013CompletedInflammatory Bowel Diseases
-
NCT02636517Enrolling by invitationCrohn's Disease | Ulcerative Colitis | Inflammatory Bowel Disease | Clostridium Difficile